Cargando…
An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer
BACKGROUND: Pancreatic cancer is a deadly disease with a very low 5-year patient survival rate of 6–8%. The major challenges of eliminating pancreatic cancer are treatment resistance and stromal barriers to optimal drug access within the tumor. Therefore, effective molecular targeting drugs with hig...
Autores principales: | Ling, Xiang, Wu, Wenjie, Fan, Chuandong, Xu, Chao, Liao, Jianqun, Rich, Laurie J., Huang, Ruea-Yea, Repasky, Elizabeth A., Wang, Xinjiang, Li, Fengzhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169080/ https://www.ncbi.nlm.nih.gov/pubmed/30285798 http://dx.doi.org/10.1186/s13046-018-0899-8 |
Ejemplares similares
-
FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance
por: Westover, David, et al.
Publicado: (2015) -
New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies
por: Westover, David, et al.
Publicado: (2015) -
FL118, acting as a ‘molecular glue degrader’, binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c‐Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy
por: Ling, Xiang, et al.
Publicado: (2022) -
Mutant Kras as a Biomarker Plays a Favorable Role in FL118-Induced Apoptosis, Reactive Oxygen Species (ROS) Production and Modulation of Survivin, Mcl-1 and XIAP in Human Bladder Cancer
por: Santha, Sreevidya, et al.
Publicado: (2020) -
A Novel Small Molecule FL118 That Selectively Inhibits Survivin, Mcl-1, XIAP and cIAP2 in a p53-Independent Manner, Shows Superior Antitumor Activity
por: Ling, Xiang, et al.
Publicado: (2012)